Could skipping a common painkiller improve cancer pain treatment?
NCT ID NCT04951804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a procedure called EUS-guided celiac plexus neurolysis (EUS-CPN) to help manage pain from pancreatic cancer. Doctors usually inject a numbing drug (bupivacaine) before alcohol to prevent pain, but it's unclear if it helps or might even reduce the procedure's effectiveness. The trial will compare pain levels in 180 adults who get the standard injection versus those who skip the numbing drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre de recherche du Centre hospitalier de l'Université de Montréal
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?